product summary
Loading...
company name : 
Miltenyi Biotec
product type : 
antibody
product name : 
CD31 Antibody, anti-human, APC, REAfinity™
catalog : 
130-110-670
quantity : 
100 tests in 200 µL
price : 
325 USD
clonality : 
monoclonal
host : 
human
conjugate : 
APC
clone name : 
REA730
reactivity : 
human
application : 
immunohistochemistry, flow cytometry
more info or order : 
citations: 2
| Published Application/Species/Sample/Dilution | Reference | 
|---|---|
| 
 | |
| Kimmig S, Przybylski G, Schmidt C, Laurisch K, Möwes B, Radbruch A, et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med. 2002;195:789-94 pubmed  | 
product information
MB Cataloge Number : 
130-110-670
Catalog Number : 
130-110-670
Product Name : 
CD31 Antibody, anti-human, APC, REAfinity™
Product Type : 
Primary antibodies, Recombinant antibodies
Host Species : 
recombinant human IgG1
Clonality : 
monoclonal
Conjugation : 
APC
Antigen Modification : 
CD31
Clone Name : 
REA730
Isotype : 
REA Control Antibody (S), human IgG1
Size : 
100 tests in 200 µL
US List Price : 
325 USD
Product Description : 
Identification and enumeration of CD31+ cells by flow cytometry
ALTnames : 
PECAM-1, EndoCAM, GPIIa, PECA1
Specificity : 
human
Concentration : 
1:50
Uses : 
For research use only
Application Summary : 
Flow cytometry
Storage : 
Store protected from light at 2–8 °C. Do not freeze.
more info or order : 
company information

Miltenyi Biotec
Friedrich-Ebert-Strae 68
51429 Bergisch Gladbach
51429 Bergisch Gladbach
macs@miltenyibiotec.com 
https://www.miltenyibiotec.com1 800 FOR MACS
headquarters: Germany
related products
browse more products
- CD31 Antibody, anti-human, VioBlue®, REAfinity™ | 130-110-812
- CD31 Antibody, anti-human, VioBlue®, REAfinity™ | 130-110-674
- CD31 Antibody, anti-human, VioGreen™, REAfinity™ | 130-110-813
- CD31 Antibody, anti-human, VioGreen™, REAfinity™ | 130-110-675
- CD31 Antibody, anti-human, PE-Vio® 770, REAfinity™ | 130-110-809
questions and comments
